#TLPH

Latest posts tagged with #TLPH on Bluesky

Trending

#MJF Tribute #Javier Bardem #WBC #Marty Supreme #Andrade #Jessie Buckley #Academy Awards #MBJ #Autumn Durald Arkapaw #Wallace #MJF Tribute #Javier Bardem #WBC #Marty Supreme #Andrade #Jessie Buckley #Academy Awards #MBJ #Autumn Durald Arkapaw #Wallace

Posts tagged #TLPH

StockTitan

@stocktitan.net

1 week ago

Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial Talphera (Nasdaq: TLPH) announced it has enrolled 35 of 70 patients (50%) in the NEPHRO-CRRT registrational trial as of March 2, 2026. The company said it reduced total enrollment by nearly 60%, refocused sites on medical ICUs with nephrologist PIs, and achieved >90% enrollment from new sites.Talphera will host a virtual investor and analyst event on March 23, 2026 at 11:00 am ET featuring nephrologists Dr. Blaithin McMahon and Dr. Joao Teixeira; a replay will be available for 90 days.

#TLPH Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial

www.stocktitan.net/news/TLPH/talphera-annou...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

17 Patients Enrolled: Talphera's NEPHRO CRRT Trial Hits Critical Milestone for Specialty Drug Development Specialty pharma Talphera reaches 17-patient enrollment in 70-patient NEPHRO CRRT trial, achieving 25% enrollment. New clinical sites drive 90% of enrollments, on track for end-2025 completion.

#TLPH Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial

www.stocktitan.net/news/TLPH/talphera-annou...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update Talphera (Nasdaq: TLPH) reported Q2 2025 financial results and provided updates on its NEPHRO clinical study. The company has enrolled 15 patients in the registrational study, which remains on track for completion by year-end. Cash position stood at $6.8 million as of June 30, 2025.Key financial metrics include a net loss of $3.5 million ($0.10 per share) in Q2 2025, improved from $3.8 million loss in Q2 2024. Operating expenses decreased to $3.7 million from $4.3 million year-over-year. The company secured a three-tranche financing of up to $14.8 million, with the first tranche of $4.9 million closed in April 2025.Talphera revised its 2025 cash operating expense guidance to $16-17 million, down from the previous $17-19 million range.

#TLPH Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/TLPH/talphera-annou...

0 0 0 0

Ramon Payno Jr

@itsramonpaynojr.bsky.social

9 months ago

ANG BAGONG KAMPEON NG Mpl Philippines SEASON 15 Team Liquid PH (@teamliquid.com)

#LetsGoLiquid #TeamLiquid #TeamLiquidPH #TL #TLPH #TLWIN #TLPHWIN
#MPLPhilippines #MPLPH #MPLPHChampionsArena #MPLPHSeason15 #MPLPHS15 #MPLPHS15Playoffs
#LakasNgPinas #HeroesWithIn
#MPLGrandFinals
#MPLPHGrandFinals

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update Talphera (NASDAQ: TLPH) reported its Q1 2025 financial results and provided corporate updates. The company's cash position stands at $9.8 million after including proceeds from April's private placement financing. Key highlights include: FDA approval to reduce NEPHRO CRRT clinical study patients from 166 to 70, with 90% power for the primary endpoint. The company secured up to $14.8 million in financing led by existing investors, with the first tranche of $4.4 million closed in April 2025. Q1 2025 financial results showed a net loss of $2.7 million ($0.10 per share), improved from $4.0 million loss in Q1 2024. Operating expenses decreased to $2.9 million from $4.2 million year-over-year. The company activated three new clinical study sites in 2025 and expects five more by mid-year, targeting study completion by year-end.

#TLPH Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/TLPH/talphera-annou...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

FDA Green Light: Talphera Slashes Trial Size by 58% as Q4 Losses Drop 57% FDA approves major reduction in NEPHRO trial size, accelerating completion timeline. Q4 shows 35% cost reduction and secured $14.8M financing. Full analysis inside.

#TLPH Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/TLPH/talphera-annou...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Talphera's NEPHRO CRRT Study Gains FDA Backing for Accelerated Patient Enrollment FDA approves key protocol changes for Talphera's nafamostat CRRT study, including expanded patient criteria and potential reduction in study size. Year-end completion targeted.

#TLPH Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study

www.stocktitan.net/news/TLPH/talphera-annou...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#TLPH Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/TLPH/talphera-annou...

0 0 0 0